This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

Certificate of Mailing [37 CFR 1.8(a)]

1600

I hereby certify that this paper and the documents referred to as attached therein are being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail addressed to the:

Commissioner for Parent P. Box 1450, Alexandria, VA 22313-1450.

NAME OF THE PARTY OF THE PARTY

<u>Denise Ortega</u> Name

March 3, 2004

Date

Signature Ottogg

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bruce M. Bowman

Group: 1600

Serial No.: 09/480,389

Group Art Unit: 1642

Filed

: January 11, 2000

Examiner: A. Holleran

For

Immunoassays to Detect Diseases or Disease

Susceptibility Traits

SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR SECTIONS 1.56, 1.97 AND 1.98

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Washington, D.C. 20231

Sir:

The accompanying PTO Form 1449 is submitted pursuant to 37 CFR Sections 1.56, 1.97 and 1.98, directing Applicants to submit literature and information that may be considered material to the examination of the claims of an application.

Applicants respectfully submit that the instant Supplementary Information Disclosure Statement (IDS) is being submitted before a final office action under 37 CFR § 1.113. Therefore, the instant Supplementary IDS, in accordance with 37 CFR § 1.97(c).

180 00 00

04/15/2004 TBESHAH1 00000020 09480389

shall be considered by the Office if filed by the applicant after the period specified in paragraph (b) of this section, provided that the information disclosure statement is filed before the mailing date of either a final action under §1.113, or a notice of allowance under §1.311, whichever occurs first and is accompanied by either:

. . .

(2) The fee set forth in §1.17(p).

Accompanying this statement is a request for payment by credit card of the fee as set forth in § 1.17(p). Should any additional fees be determined to be necessary in connection with this paper, Applicants respectfully request that any such additional fees be charged to Deposit Account No. 12-0615.

Applicants respectfully submit that the "filing of an information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in Section 1.56(b)" [37 CFR Section 1.97(h)]; and that an information disclosure statement filed in accordance with 37 CFR Section 1.97 "shall not be construed as a representation that a search has been made." [37 CFR Section 1.97(g)]

Further the identification of any document herein is not intended to be, and, Applicants respectfully submit, should not be construed as being, an admission that such a document, in fact, constitutes "prior art" within the meaning of the applicable laws, since, for example, a given document may have a later effective date than at first seems apparent, or the

document may have an effective date which can be antedated.

Applicants respectfully conclude on this point that the "prior art" status of any document is a matter to be resolved during prosecution.

Thus, Applicants respectfully conclude that the citation of references herein is not intended to be an admission that any of the references are considered to be material or to constitute prior art, or that any of the references either alone or in combination with any other references would be sufficient to render any of the claims of the above-identified patent application unpatentable.

Respectfully submitted,

Leona L. Lauder

Attorney for Applicants Registration No. 30,863

Dated: March 3, 2004

INFORMATION DISCLOSURE CITATION				Application Number
			CATX-N Applicant(s)	09/480,389
(Use several sheets if n cessary)			Bruce M. Bowman	
MAR 0 8 2004 S			•	Group Art Unit
*EXAMINER			January 11, 2000	1642
INITIAL		OTHER DOCUMENT And Author, Title, Date, Pertinent Pages, Etc.)		
		Boddrich et al., "Reduced Neurofibromin Content but Normal Gap Activity in a Patient with Neurofibromatosis Type 1 Caused by a Five Base Pair Duplication in Exon 12B of the NF1 Gene," Biochemical and Biophysical Research		
•	<u>Communictions, 214(3)</u> : 895-904 (Sept. 25, 1995)			
		Czech et al., "Proteolytical processing of mutated human amyloid precursor protein in transgenic mice," Molecular Brain Research, 47: 108-116 (1997)		
:		Research, 47: 108-116 (1997)		
		Mortola and Nasto, "Brown adipose tissue and its uncoupling protein in chronically hypoxic rats," Clinical Science, 93: 349-354 (1997)		
		` '		
			•	
			· ·	
				
			, , , , , , , , , , , , , , , , , , ,	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

EXAMINER